Randall ME, et al. - In this trial including eligible high-intermediate and high-risk early-stage endometrial carcinoma patients, researchers compared recurrence-free survival between vaginal cuff brachytherapy and chemotherapy (VCB/C) vs pelvic radiation therapy (RT). In a random manner, treatment was assigned between RT (45 to 50.4 Gy over 5 weeks) or VCB followed by intravenous paclitaxel 175 mg/m² (3 hours) plus carboplatin (area under the curve, 6) every 21 days for three cycles. Findings did not reveal any superiority of VCB/C vs pelvic RT. VCB/C was associated with greater acute toxicity, while late toxicity was comparable. Good tolerability, efficacy, and appropriateness with pelvic RT alone was evident in adjuvant therapy for high-risk early-stage endometrial carcinomas of all histologies.